Skip to content
Pediatric Ophthalmology & Strabismus

Cerebro-oculo-facio-skeletal syndrome

1. What is Cerebro-oculo-facio-skeletal Syndrome?

Section titled “1. What is Cerebro-oculo-facio-skeletal Syndrome?”

Cerebro-oculo-facio-skeletal syndrome (COFS) is a rare congenital autosomal recessive disorder that impairs development of the brain, head, eyes, limbs, and face. It is caused by defects in the nucleotide excision repair (NER) pathway (Suzumura & Arisaka, 2010 [PMID: 20687508]).

Only 14 cases were recorded between 1974 and 2010 (Suzumura & Arisaka, 2010 [PMID: 20687508]). A documented case after 2010 includes a familial recurrence reported by Sirchia et al. in 2021, with biallelic ERCC5 mutations (Sirchia et al., 2021 [PMID: 33766032]).

In previously reported case series, most patients died by 30 months of age. The main causes of death are failure to thrive due to feeding difficulties and recurrent aspiration pneumonia (Suzumura & Arisaka, 2010 [PMID: 20687508]; Reunert et al., 2021 [PMID: 33369099]).

Q What is the prognosis of COFS syndrome?
A

The prognosis is extremely poor. In most cases, survival does not exceed 30 months. Failure to thrive due to feeding difficulties and recurrent aspiration pneumonia are the main causes of death.

Because COFS involves severe developmental delay, it is difficult for patients to report symptoms. Multisystem abnormalities are evident from birth.

Clinical findings of COFS are broadly divided into ophthalmic, craniofacial, neurological, and musculoskeletal findings.

Ophthalmic Findings

Blepharophimosis: Narrowing of the palpebral fissure.

Microphthalmia: Bilateral ocular hypoplasia.

Congenital cataract: Lens opacity present at birth.

Nystagmus: Involuntary eye movements.

Orbital hypertelorism: Increased distance between the eyes.

Craniofacial

Microcephaly: The head circumference is significantly small.

Micrognathia: Underdevelopment of the lower jaw is observed.

Microstomia and cleft palate: Accompanied by oral morphological abnormalities.

High-arched palate: The palate is high and arched.

Short neck: The neck is shortened.

Neurological findings

Decreased or absent tendon reflexes: Deep tendon reflexes throughout the body are reduced.

Sensorineural hearing loss: Hearing loss due to damage to the inner ear or auditory nerve.

Cognitive developmental disorder: Accompanied by severe developmental delay.

Musculoskeletal system

Arthrogryposis: Multiple joint contractures are present.

Flexion contractures: Particularly prominent in the elbow and knee joints.

Hypotonia: Decreased muscle tone throughout the body.

Syndactyly and rocker-bottom feet: Associated with limb malformations.

Osteoporosis: Reduced bone density is observed.

COFS is caused by mutations in genes of the transcription-coupled nucleotide excision repair (TC-NER) pathway. Defects in the NER pathway lead to accumulation of genetic mutations, manifesting as developmental disorders in multiple organs.

The causative genes are as follows (Suzumura & Arisaka, 2010 [PMID: 20687508]; Laugel et al., 2008 [PMID: 18628313]).

  • CSB (ERCC6): Also a causative gene for Cockayne syndrome. A founder mutation in northern Finland has been identified (Jaakkola et al., 2010 [PMID: 20456449])
  • XPD (ERCC2) and XPG (ERCC5): Also causative genes for xeroderma pigmentosum (Reunert et al., 2021 [PMID: 33369099]; Le Van Quyen et al., 2020 [PMID: 32052936])
  • ERCC1: A core repair factor in the NER pathway

Consanguineous marriage is an important risk factor for COFS. Due to autosomal recessive inheritance, couples who are both carriers have an increased risk of having an affected child.

Microarray analysis and targeted molecular testing for the following NER-related genes are useful for identifying carriers:

  • ERCC1, ERCC2, ERCC5, ERCC6
  • KIAA1109, PHGDH, FKTN

COFS is clinically diagnosed based on a combination of the following findings (Laugel et al., 2008 [PMID: 18628313]).

  • Microcephaly
  • Congenital cataract
  • Microphthalmia
  • Multiple joint contractures
  • Growth failure and developmental delay
  • Facial dysmorphism: prominent nasal root, prominent upper lip

To confirm DNA repair defects in the NER pathway. The following tests are available.

  • Microarray analysis: Comprehensive screening for known mutations
  • Next-generation sequencing (NGS) panel: Targeted analysis of NER-related genes
  • Whole exome sequencing (WES): Useful for identifying novel mutations
  • Whole genome sequencing (WGS): Most comprehensive analysis
  • X-ray: Systemic bone hypomineralization, microcephaly
  • CT: Intracranial calcifications
  • MRI: Progressive cerebral demyelination, ventriculomegaly, cerebellar hypoplasia, partial or complete agenesis of the corpus callosum
  • Ultrasound (prenatal diagnosis): Clenched hands with overlapping fingers, rocker-bottom feet, bilateral microphthalmia with cataract formation, micrognathia with low-set ears. COFS should be considered in the differential diagnosis when intrauterine growth restriction, microcephaly, joint contractures, and ocular abnormalities are present (Le Van Quyen et al., 2020 [PMID: 32052936]; Sirchia et al., 2021 [PMID: 33766032])

The differential diagnosis of COFS directly determines the treatment strategy. In particular, distinguishing it from Cockayne syndrome is extremely important when deciding on the indication for cataract surgery.

DiseaseDifference from COFSCataract surgery
Cockayne syndromeSurvival approximately 12 yearsBeneficial
COFS syndromeSurvival approximately 30 monthsUsually not performed

Other differential diagnoses are as follows.

  • Alkuraya-Kucinskas syndrome
  • Neu-Laxova syndrome
  • Smith-Lemli-Opitz syndrome
  • Micro syndrome (Warburg-Micro syndrome)
  • Martsolf syndrome
  • CAMFAK syndrome
  • Costello syndrome
  • Muscular dystrophy-dystroglycanopathy type A4
  • Primary microcephaly type 10
Q How is it differentiated from Cockayne syndrome?
A

Both COFS and Cockayne syndrome result from defects in the NER pathway, but their clinical courses differ. The survival period for Cockayne syndrome is about 12 years, and cataract surgery is beneficial for improving visual outcomes before the onset of retinal dystrophy. In contrast, the survival period for COFS is about 30 months, and cataract surgery is not typically performed.

There is no curative treatment for COFS. Ophthalmic findings are managed symptomatically according to standard protocols.

In COFS, cataract surgery is usually not performed. Because survival is extremely short, approximately 30 months, the balance of risks and benefits of surgery is difficult to establish. This contrasts with Cockayne syndrome, where survival is about 12 years and cataract surgery is recommended.

  • Nutritional management: Supportive therapy such as tube feeding for feeding disorders
  • Respiratory management: Prevention and treatment of aspiration pneumonia
  • Rehabilitation: Physical therapy for joint contractures

6. Pathophysiology and detailed pathogenesis

Section titled “6. Pathophysiology and detailed pathogenesis”

The NER pathway is a crucial mechanism for repairing DNA damage caused by ultraviolet light and other factors. In COFS, defects in this pathway lead to accumulation of DNA damage, causing developmental disorders in multiple organs.

Transcription-coupled NER (TC-NER) is a repair mechanism that operates when RNA polymerase II stalls at a DNA damage site during transcription. The causative genes of COFS—CSB, XPD, XPG, and ERCC1—are all components of this pathway.

Mutations in the same group of genes in the TC-NER pathway can lead to different clinical presentations such as COFS, Cockayne syndrome, and xeroderma pigmentosum, depending on the site and type of mutation. COFS is considered the most severe form within the Cockayne spectrum, with developmental impairment progressing from before birth (Laugel et al., 2008 [PMID: 18628313]).

  1. Suzumura H, Arisaka O. Cerebro-oculo-facio-skeletal syndrome. Adv Exp Med Biol. 2010;685:210-214. PMID: 20687508
  2. Laugel V, Dalloz C, Tobias ES, et al. Cerebro-oculo-facio-skeletal syndrome: three additional cases with CSB mutations, new diagnostic criteria and an approach to investigation. J Med Genet. 2008;45(9):564-571. PMID: 18628313
  3. Jaakkola E, Mustonen A, Olsen P, et al. ERCC6 founder mutation identified in Finnish patients with COFS syndrome. Clin Genet. 2010;78(6):541-547. PMID: 20456449
  4. Reunert J, van den Heuvel A, Rust S, Marquardt T. Cerebro-oculo-facio-skeletal syndrome caused by the homozygous pathogenic variant Gly47Arg in ERCC2. Am J Med Genet A. 2021;185(3):896-901. PMID: 33369099
  5. Le Van Quyen P, Calmels N, Bonnière M, et al. Prenatal diagnosis of cerebro-oculo-facio-skeletal syndrome: Report of three fetuses and review of the literature. Am J Med Genet A. 2020;182(6):1457-1466. PMID: 32052936
  6. Sirchia F, Fantasia I, Feresin A, et al. Prenatal findings of cataract and arthrogryposis: recurrence of cerebro-oculo-facio-skeletal syndrome and review of differential diagnosis. BMC Med Genomics. 2021;14(1):89. PMID: 33766032

Copy the article text and paste it into your preferred AI assistant.